Order Article Reprints

Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke Y-SE, Lieber M, Iordanidis K, Manns MP, et al. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines. 2021; 9(4):353. https://doi.org/10.3390/biomedicines9040353

Hupa-Breier, Katharina Luise, Janine Dywicki, Björn Hartleben, Freya Wellhöner, Benjamin Heidrich, Richard Taubert, Young-Seon Elisabeth Mederacke, Maren Lieber, Konstantinos Iordanidis, Michael P. Manns, and et al. 2021. "Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH" Biomedicines 9, no. 4: 353. https://doi.org/10.3390/biomedicines9040353

Hupa-Breier, K. L., Dywicki, J., Hartleben, B., Wellhöner, F., Heidrich, B., Taubert, R., Mederacke, Y.-S. E., Lieber, M., Iordanidis, K., Manns, M. P., Wedemeyer, H., Hardtke-Wolenski, M., & Jaeckel, E. (2021). Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines, 9(4), 353. https://doi.org/10.3390/biomedicines9040353